open access

Vol 89, No 11 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-11-30
Get Citation

The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer

Mehmet Ünsal, Gunsu Kimyon Comert, Alper Karalok, Derman Basaran, Osman Turkmen, Gokhan Boyraz, Tolga Tasci, Sevgi Koc, Nurettin Boran, Gokhan Tulunay, Taner Turan
DOI: 10.5603/GP.a2018.0103
·
Pubmed: 30508211
·
Ginekol Pol 2018;89(11):599-606.

open access

Vol 89, No 11 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-11-30

Abstract

Objectives: To evaluate the predictive value of preoperative CA125 in extra-uterine disease and its association with poor
prognostic factors in endometrioid-type endometrial cancer (EC).
Material and methods: A total of 423 patients with pathologically proven endometrioid-type EC were included in the
study. The association between preoperative CA125 level and surgical–pathological factors was evaluated. The conventional cut-off value was defined as 35 IU/mL.
Results: A high CA125 level ( > 35 IU/mL) was significantly associated with all of the studied poor prognostic factors,
except grade. The risk of lymph node metastasis (LNM) increased from 15.9% to 45.7% when CA125 level was > 35 IU/mL (p < 0.05). The optimal cut-off value for the prediction of LNM in patients aged > 50 years was determined to be 16 IU/mL (sensitivity, specificity, positive predictive value, and negative predictive value were 71%, 60%, 35%, and 87%, respectively.)
Conclusions: Preoperative CA125 level was significantly related with the extent of the disease and LNM. The age-dependent cut-off level of CA125 can improve the prediction of LNM in endometrioid-type EC. For older patients, CA125 level of > 16 IU/ml could be used to predict LNM. However, further studies are needed to evaluate the appropriate cut-off level of CA125 for younger patients.

Abstract

Objectives: To evaluate the predictive value of preoperative CA125 in extra-uterine disease and its association with poor
prognostic factors in endometrioid-type endometrial cancer (EC).
Material and methods: A total of 423 patients with pathologically proven endometrioid-type EC were included in the
study. The association between preoperative CA125 level and surgical–pathological factors was evaluated. The conventional cut-off value was defined as 35 IU/mL.
Results: A high CA125 level ( > 35 IU/mL) was significantly associated with all of the studied poor prognostic factors,
except grade. The risk of lymph node metastasis (LNM) increased from 15.9% to 45.7% when CA125 level was > 35 IU/mL (p < 0.05). The optimal cut-off value for the prediction of LNM in patients aged > 50 years was determined to be 16 IU/mL (sensitivity, specificity, positive predictive value, and negative predictive value were 71%, 60%, 35%, and 87%, respectively.)
Conclusions: Preoperative CA125 level was significantly related with the extent of the disease and LNM. The age-dependent cut-off level of CA125 can improve the prediction of LNM in endometrioid-type EC. For older patients, CA125 level of > 16 IU/ml could be used to predict LNM. However, further studies are needed to evaluate the appropriate cut-off level of CA125 for younger patients.

Get Citation

Keywords

preoperative CA125; endometrial cancer; lymph node metastases; poor prognostic factors

About this article
Title

The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer

Journal

Ginekologia Polska

Issue

Vol 89, No 11 (2018)

Pages

599-606

Published online

2018-11-30

DOI

10.5603/GP.a2018.0103

Pubmed

30508211

Bibliographic record

Ginekol Pol 2018;89(11):599-606.

Keywords

preoperative CA125
endometrial cancer
lymph node metastases
poor prognostic factors

Authors

Mehmet Ünsal
Gunsu Kimyon Comert
Alper Karalok
Derman Basaran
Osman Turkmen
Gokhan Boyraz
Tolga Tasci
Sevgi Koc
Nurettin Boran
Gokhan Tulunay
Taner Turan

References (24)
  1. Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015; 65(1): 5–29.
  2. Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. The Lancet. 2016; 387(10023): 1094–1108.
  3. Burke W, Orr J, Leitao M, et al. Endometrial cancer: A review and current management strategies: Part I. Gynecologic Oncology. 2014; 134(2): 385–392.
  4. Chao A, Tang YH, Lai CH, et al. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecologic Oncology. 2013; 129(3): 500–504.
  5. Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer. 2015; 15: 396.
  6. Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstetricia et Gynecologica Scandinavica. 2006; 85(12): 1501–1505.
  7. Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002; 86(1): 28–33.
  8. Kim H, Park CY, Lee JM, et al. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: A multi-center study. Gynecologic Oncology. 2010; 118(3): 283–288.
  9. Han SS, Lee S, Kim D, et al. Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. Acta Obstetricia et Gynecologica Scandinavica. 2010; 89(2): 168–174.
  10. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105(2): 103–104.
  11. Studies HUIoP. 2013 Turkey Demographic and Health Survey. Hacettepe University Institute of Population Studies,TR Ministry of Development and TÜBİTAK, Ankara, Turkey. 2014.
  12. Turan T, Ureyen I, Duzguner I, et al. Analysis of Patients With Stage IIIC Endometrial Cancer. International Journal of Gynecological Cancer. 2014; 24(6): 1033–1041.
  13. Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005; 50(8): 585–590.
  14. Yang B, Shan B, Xue X, et al. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models. PLOS ONE. 2016; 11(5): e0155145.
  15. Nicklin J, Janda M, Gebski V, et al. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. International Journal of Cancer. 2011; 131(4): 885–890.
  16. Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997; 90(3): 441–447.
  17. Schmidt M, Segev Y, Sadeh R, et al. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma. International Journal of Gynecological Cancer. 2018; 28(7): 1311–1317.
  18. Dotters D. Preoperative CA 125 in endometrial cancer: Is it useful? American Journal of Obstetrics and Gynecology. 2000; 182(6): 1328–1334.
  19. Kang S, Nam JH, Bae DS, et al. Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer. 2016; 123(2): 263–272.
  20. Ginath S, Menczer J, Fintsi Y, et al. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer. 2002; 12(4): 372–375.
  21. Choi YS, Koh SB, Ahn JY, et al. Usefulness of preoperative CA125 level in decision making of lymphadenectomy in endometrial cancer patients. Korean J Obstet Gynecol. 2005; 48: 2877–87.
  22. Koper NP, Massuger LF, Thomas CM, et al. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Res. 1998; 18(3B): 1897–1902.
  23. Yildiz A, Yetimalar H, Kasap B, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2012; 164(2): 191–195.
  24. Nikolaou M, Kourea HP, Tzelepi V, et al. The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma. J BUON. 2014; 19(1): 198–202.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl